Tempus AI Inc. (NASDAQ: TEM) announced a strategic collaboration with the Keck School of Medicine of USC and Keck Medicine of USC, marking a significant expansion of its healthcare AI platform into a major Southern California health system. The partnership, disclosed Thursday, will initially focus on precision oncology, leveraging Tempus's molecular testing and clinical trial-matching tools across USC's network of hospitals and clinics, which collectively handle more than 1.5 million patient visits annually. Financial terms were not disclosed.
The deal grants Tempus access to a broader slice of hospital operations, extending beyond typical lab services or pharmaceutical partnerships. The integration will cover the USC Norris Comprehensive Cancer Center, Keck Hospital of USC, USC Verdugo Hills Hospital, and affiliated clinics. Precision medicine, which tailors treatment based on a patient's genetic profile, tumor characteristics, and medical history, is at the core of this initiative. The collaboration may eventually expand into cardiology, neurology, and radiology.
Tempus shares traded at $51.70 midday Friday, with a market capitalization of approximately $9.0 billion. The stock moved in a narrow range between $50.57 and $52.64 during the session. Investors are watching for the company's first-quarter earnings release scheduled for May 5. In February, Tempus projected 2026 revenue of $1.59 billion and adjusted EBITDA of around $65 million.
The USC collaboration encompasses four key areas: clinical testing, genomic profiling (including tests for genetic and disease markers), trial matching, care-gap alerts, and joint research. Trial matching aims to identify patients eligible for targeted therapies and clinical studies, a process that remains slow and largely manual in oncology. Vasiliki Anest, chief innovation officer at Keck School of Medicine, described the effort as aligning research, clinical care, and innovation priorities. Steven Shapiro, USC's senior vice president for health affairs, emphasized that the deal is designed to guide patients toward the most appropriate clinical trials and treatments.
Ezra Cohen, Tempus's chief medical officer of oncology, stated that the partnership could create a powerful, integrated ecosystem linking Tempus's platform with USC's research and clinical operations. However, translating this vision into routine clinical practice remains a challenge. April has been a busy month for Tempus, with several other announcements including a Gilead oncology R&D collaboration, the rollout of automated active follow-up for oncology care, and a Predicta Biosciences assay partnership.
Tempus faces stiff competition from established players in genomic profiling and cancer diagnostics, including Roche's Foundation Medicine, Guardant Health, and NeoGenomics. In this segment, the size of a company's data repository and hospital connections can drive both testing volumes and drug development deals. The USC partnership does not specify how much or when Tempus might see a revenue boost, leaving investors to gauge its financial impact.
The company is also under scrutiny from a federal class-action lawsuit filed April 15 in Illinois, alleging improper acquisition and sharing of genetic data linked to its Ambry Genetics acquisition. The allegations remain unproven, and Tempus has not yet responded in court. The USC deal presents a fresh opportunity for Tempus to demonstrate its value proposition: can AI combined with genetics truly transform patient care, and will hospitals commit to the platform? Investors will look to the May earnings call for signs of whether this approach is accelerating growth or merely adding to a growing list of partnerships without tangible results.
